Novartis Stock Forecast, Price & News

+0.36 (+0.38 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.27 million shs
Average Volume1.97 million shs
Market Capitalization$215.48 billion
P/E Ratio27.05
Dividend Yield2.22%
30 days | 90 days | 365 days | Advanced Chart
Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

Novartis logo

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.97 out of 5 stars

Medical Sector

55th out of 2,100 stocks

Pharmaceutical Preparations Industry

23rd out of 831 stocks

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Novartis (NYSE:NVS) Frequently Asked Questions

Is Novartis a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novartis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View analyst ratings for Novartis
or view top-rated stocks.

What stocks does MarketBeat like better than Novartis?

Wall Street analysts have given Novartis a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novartis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, July 20th 2021.
View our earnings forecast for Novartis

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Monday, April, 26th. The company reported $1.52 EPS for the quarter, missing the Zacks' consensus estimate of $1.54 by $0.02. The company had revenue of $12.41 billion for the quarter, compared to analysts' expectations of $12.63 billion. Novartis had a net margin of 16.31% and a trailing twelve-month return on equity of 24.15%. Novartis's revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.56 earnings per share.
View Novartis' earnings history

How has Novartis' stock price been impacted by COVID-19?

Novartis' stock was trading at $82.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVS shares have increased by 14.6% and is now trading at $94.15.
View which stocks have been most impacted by COVID-19

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Wednesday, January 27th. Investors of record on Friday, March 5th will be paid a dividend of $3.3784 per share on Monday, March 15th. This represents a dividend yield of 2.2%. The ex-dividend date of this dividend is Thursday, March 4th. This is an increase from Novartis's previous annual dividend of $3.04.
View Novartis' dividend history

Is Novartis a good dividend stock?

Novartis pays an annual dividend of $2.08 per share and currently has a dividend yield of 2.22%. Novartis does not yet have a strong track record of dividend growth. The dividend payout ratio of Novartis is 36.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novartis will have a dividend payout ratio of 30.91% next year. This indicates that Novartis will be able to sustain or increase its dividend.
View Novartis' dividend history.

What price target have analysts set for NVS?

11 Wall Street analysts have issued 12 month target prices for Novartis' stock. Their forecasts range from $105.00 to $112.00. On average, they expect Novartis' share price to reach $108.50 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price.
View analysts' price targets for Novartis
or view top-rated stocks among Wall Street analysts.

Who are Novartis' key executives?

Novartis' management team includes the following people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 45, Pay $5.17M) (LinkedIn Profile)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 56, Pay $2.72M) (LinkedIn Profile)
  • Mr. Steffen Lang Ph.D., Global Head of Technical Operations (Age 54, Pay $2.05M)
  • Dr. Klaus Moosmayer Ph.D., Chief Ethics, Risk & Compliance Officer (Age 53, Pay $1.35M) (LinkedIn Profile)
  • Mr. Steven Baert, Chief People & Organization Officer (Age 47, Pay $2.23M) (LinkedIn Profile)
  • Dr. John Tsai, Head of Global Drug Devel. & Chief Medical Officer (Age 54, Pay $2.34M) (LinkedIn Profile)
  • Mr. Robert Weltevreden, Head of Customer & Technology Solutions (Age 52, Pay $1.59M)
  • Ms. Susanne Schaffert Ph.D., Pres of Novartis Oncology (Age 54, Pay $3.06M) (LinkedIn Profile)
  • Mr. Richard Saynor, Chief Exec. Officer of Sandoz (Age 54, Pay $3.86M)
  • Dr. James E. Bradner, Pres of Novartis Institutes for Biomedical Research (Age 49, Pay $3.2M) (LinkedIn Profile)

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis CEO Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among Novartis' employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novartis' key competitors?

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (0.90%), Loomis Sayles & Co. L P (0.86%), Fisher Asset Management LLC (0.42%), Franklin Resources Inc. (0.37%), Boston Partners (0.26%) and Mawer Investment Management Ltd. (0.21%).

Which major investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Schafer Cullen Capital Management Inc, Mawer Investment Management Ltd., Clearbridge Investments LLC, Primecap Management Co. CA, Fiera Capital Corp, Manning & Napier Group LLC, and The Manufacturers Life Insurance Company.

Which major investors are buying Novartis stock?

NVS stock was acquired by a variety of institutional investors in the last quarter, including Cullen Capital Management LLC, Parnassus Investments CA, BlackRock Inc., Fisher Asset Management LLC, Arrowstreet Capital Limited Partnership, Mondrian Investment Partners LTD, Natixis Advisors L.P., and Envestnet Asset Management Inc..

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $94.15.

How much money does Novartis make?

Novartis has a market capitalization of $215.48 billion and generates $48.66 billion in revenue each year. The company earns $8.07 billion in net income (profit) each year or $5.75 on an earnings per share basis.

How many employees does Novartis have?

Novartis employs 103,914 workers across the globe.

Does Novartis have any subsidiaries?

The following companies are subsidiares of Novartis: Admune Therapeutics, Advanced Accelerator Applications, Alcon, Amblyotech, AveXis, CellforCure, Chiron Corporation, CoStim Pharmaceuticals, Corthera, Encore Vision, Endocyte, Fougera Pharmaceuticals, Hexal, Novartis Inflammasome Research, Protez Pharmaceuticals, Selexys Pharmaceuticals Corporation, Spinifex Pharmaceuticals, The Medicines Company, Vedere Bio, Xiidra, and Ziarco.

When was Novartis founded?

Novartis was founded in 1996.

What is Novartis' official website?

The official website for Novartis is www.novartis.com.

Where are Novartis' headquarters?

Novartis is headquartered at LICHTSTRASSE 35, BASEL V8, CH 4056.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.